Feasibility and Safety of Erythropoietin for Neuroprotection after Perinatal Arterial Ischemic Stroke

Conclusions: rhEPO in neonates with perinatal arterial ischemic stroke had no adverse effects on red blood cells, white blood cells, platelets counts, or coagulation. rhEPO, 3000 IU/kg in total, given during a 3-day period, appears to be a safe therapy. The beneficial effects remains to be demonstrated in a larger, randomized, double-blind, placebo-controlled trial.

Source: The Journal of Pediatrics - December 9, 2013 Category: Pediatrics Authors: Manon J. Benders, Niek E. van der Aa, Maurice Roks, Henrica L. van Straaten, Ivana Isgum, Max A. Viergever, Floris Groenendaal, Linda S. de Vries, Frank van Bel Tags: Original Articles Source Type: research